Antibody Discovery Market Scope And Analysis

Report Code : TIPRE00007411
Category : Biotechnology

Status : Published
No. of Pages : 180

Buy Now

Antibody Discovery Market Scope, Growth, Size and Share by 2030

Buy Now

Antibody Discovery Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 2.94 Billion
Market Size by 2030	US$ 4.92 Billion
Global CAGR (2022 - 2030)	6.7%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Antibody Type Monoclonal Antibodies Polyclonal Antibodies By Nature Human and Humanized Chimeric Murine By Service Phage Display Hybridoma Transgenic Animal Single Cell Yeast Display By End User Pharmaceutical and Biotechnology Companies Research Laboratories
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Creative Biolabs Evotec BioDuro Sundia Bruker Cellular Analysis Biocytogen Charles River Laboratories Aragen Life Sciences Pvt Ltd Twist Bioscience NanoCellect Biomedical

Key Player Analysis:

Creative Biolabs, Evotec, BioDuro-Sundia, Bruker Cellular Analysis, Biocytogen, Charles River Laboratories, Aragen Life Sciences Pvt. Ltd, Twist Bioscience, NanoCellect Biomedical, and Sartorius AG are among the key players profiled in the antibody discovery market report.

Recent Developments:

Companies operating in the antibody discovery market adopt strategic initiatives such as mergers and acquisitions, partnerships, etc. A few of the recent market developments are listed below:

In January 2024, Biocytogen Pharmaceuticals Co Ltd launched a new sub-brand named RenBiologics to represent the company’s Antibody Discovery business division. RenBiologics business is expected to cover the out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as the licensing of RenMice, a fully human antibody/TCR discovery platform of Biocytogen Pharmaceuticals.
In December 2023, Biocytogen Pharmaceuticals Co Ltd announced an antibody evaluation, option, and license agreement with Ona Therapeutics to design biopharmaceuticals against advanced cancer types. Under the terms of the agreement, Biocytogen Pharmaceuticals Co Ltd granted Ona access to evaluate its proprietary RenMice-derived fully human antibodies against a specific tumor target, with an option to exclusively license selected antibodies for the development, manufacturing, and commercialization of antibody-drug conjugates (ADCs) in mutually agreed indications and territories.
In June 2022, Evotec SE announced a collaboration with Janssen Pharmaceutica NV, one of the companies of Johnson & Johnson for drug discovery. Under the collaboration, Evotec SE is meant to evaluate its TargetAlloMod platforms for the discovery of first-in-class therapeutic candidates with novel modes of action and Janssen Pharmaceutica NV will facilitate the same.
In August 2021, Sartorius AG entered into a partnership with McMaster University to improve the manufacturing processes of antibodies and other virus-based treatments for diseases such as COVID-19, cancer, and genetic disorders. This partnership with McMaster University led to impactful research that made important treatments available at a greater scale.